---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094466"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2026-08-12T11:28:40+00:00"
generated_at: "2026-08-12T11:30:03.836657+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Milestone Q2 2026 net loss $28.6M; CARDAMYST coverage jumps to ~50% of commercial lives

## Summary
- Q2 2026 net loss of $28.6M ($0.21/share) vs $13.0M ($0.20/share) in Q2 2025.
- Product revenue $0.6M in Q2; first sales from CARDAMYST launched mid-Feb 2026.
- Cash, equivalents, short-term investments $170.6M as of June 30, 2026; runway into H2 2027.
- CARDAMYST: >800 prescribers, >1,500 scripts filled; commercial coverage now ~50% via UnitedHealthcare.
- Phase 3 ReVeRA-301 AFib-RVR trial sites activated; EMA decision on etripamil for PSVT expected H1 2027.

## SEC filing metadata
- accession: 0001104659-26-094466
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2026-08-12T11:28:40+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/0001104659-26-094466-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094466
- JSON: https://secwatch.observer/filing/0001104659-26-094466.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094466.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.